Qomel Company (9600) Fair Value & Analysis
Healthcare · SA · Market cap 336M SAR
Fair value as of: Aug 1, 2026
From 16 valuation models · updated today
Share price −4.0% over the past month.
What matters now
- The price sits above even our optimistic bull case (45.41 SAR). The favourable scenario is already priced in.
- Weak quality (33/100) and above fair value at the same time, the margin of safety is missing on both counts.
Price vs Fair Value (12 months)
12‑month range 42.50 SAR – 59.25 SAR · fair‑value band 27.24 SAR – 45.41 SAR · the 48.00 SAR price screens above the 36.33 SAR fair value. As of Aug 1, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Qomel Company (9600) currently trades at 48.00 SAR, while our model-based Fair Value estimate is 36.33 SAR, implying the stock looks roughly 24.3% overvalued today. We read business quality at 33/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Qomel Company generated revenue of 132M SAR at a net margin of 11.3%. Revenue declined 7.1% year over year. It earns a return on equity of 13.3%. Net debt stands at 17.7M SAR. Fundamentals as of Aug 1, 2026
Our scenario range runs from 27.24 SAR (bear case) to 45.41 SAR (bull case); at 48.00 SAR, the current price sits above that range. The share trades about 19% below its 52-week high and 14% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 15% fair-value upside, at -24%, 9600 screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 1, 2026. TTM = trailing twelve months.
Quality Score breakdown
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Qomel Company Limited operates as a healthcare company in Saudi Arabia. The company is involved in the sale of medicine and natural medicinal herbs. It also offers pharmaceutical and medical supplies services. The company was founded in 2007 and is headquartered in Riyadh, Saudi Arabia.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Qomel Company reported revenue of 132M SAR in FY2025 versus 61.2M SAR in FY2021, a compound +21.2%/yr. Reported net income was 15.0M SAR in FY2025, compounding +25.0%/yr from FY2021.
Is 9600 fairly valued? → Check now
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Pharmaceutical Retailers stocks, each showing price versus our Fair Value estimate (as of Aug 1, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| JD Health International Inc JDHIY | $5.33 | $7.09 | +33% |
| Alibaba Health Information Technology Limited ALBBY | $8.56 | $6.91 | -19% |
| Raia Drogasil S.A RADL3 | R$17.76 | R$14.97 | -16% |
| Yifeng Pharmacy Chain Co 603939 | ¥20.91 | ¥22.00 | +5% |
| Clicks Group CLCGY | $27.97 | $34.29 | +23% |
| Sugi Holdings SGIPF | $16.29 | $64.34 | +295% |
| Corporativo Fragua, S.A. CGSBF | $29.66 | $29.34 | -1% |
| DaShenLin Pharmaceutical Group 603233 | ¥16.68 | ¥19.21 | +15% |
| Redcare Pharmacy NV RDC | €66.40 | €124.16 | +87% |
| LBX Pharmacy Chain Joint Stock Company 603883 | ¥11.74 | ¥10.57 | -10% |
Compare Qomel Company with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Qomel Company (9600) overvalued or undervalued?
What is the fair value of 9600?
What is the quality score of 9600?
What is the revenue of Qomel Company (9600)?
What is the net profit margin of 9600?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Qomel Company and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.